Bioxyne Limited announced that subsequent to the execution of a non-binding Heads of Agreement to sell its HI-164 Oral Vaccine project together with all of its Intellectual Properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief Executive Officer of the company. In the interim, operational matters would be managed by the chairman, Mr. Tony Ho and the CFO Mr. Jarrod White.